Geron Corporation (NASDAQ:GERN) was upgraded by research analysts at MLV & Co
from a “hold” rating to a “buy” rating in a report released on Thursday. The firm currently has a $4.25 price objective on the stock, up from their previous price objective of $2.00. MLV & Co
‘s price target would suggest a potential upside of 42.62% from the company’s current price. Geron Corporation (NASDAQ:GERN) weekly performance is 39.72%. On last trading day company shares ended up $2.99. Analysts mean target price for the company is $2.00. Geron Corporation (NASDAQ:GERN) distance from 50-day simple moving average (SMA50) is 47.70%.
On June 11, ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) announced its intention to offer, subject to market and other conditions, $175 million aggregate principal amount of convertible senior notes due 2019 (the “Notes”) in a private placement. The Notes will be offered by the initial purchasers only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933 (the “Act”). Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares advanced 1.18% in last trading session and ended the day on $6.45. Gross Margin is 79.20% and its return on assets is -66.50%. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) quarterly performance is -18.39%.
Gilead Sciences, Inc. (NASDAQ:GILD) announced that its corporate presentation will be webcast from the Wells Fargo Healthcare Conference in Boston. John C. Martin, PhD, Gilead’s Chairman and Chief Executive Officer, will provide an overview of the company at the conference on Tuesday, June 17 at 10:00 a.m. Eastern Time. Gilead Sciences, Inc. (NASDAQ:GILD) shares moved up 0.06% in last trading session and was closed at $80.77, while trading in range of $80.41 – $81.39. Gilead Sciences, Inc. (NASDAQ:GILD) year to date (YTD) performance is 7.55%.
MannKind Corporation (NASDAQ:MNKD) is the talk of the pharmaceutical industry thanks to anticipated FDA decision later next month. The FDA is expected to decide whether or not it will approve Afrezza, which is MannKind’s one and only drug that is about to hit the shelves if the regulator decides favorably on its fate. The drug is presented as inhalable insulin for the combating of diabetes. MannKind Corporation (NASDAQ:MNKD) ended the last trading day at $10.65. Company weekly volatility is calculated as 5.22% and price to cash ratio as 115.61. MannKind Corporation (NASDAQ:MNKD) showed a negative weekly performance of -0.47%.
bluebird bio Inc (NASDAQ:BLUE) released initial positive clinical data from its HGB-205 clinical study of its LentiGlobin BB305 product candidate in beta-thalassemia major subjects at the 19th Annual Congress of the European Hematology Association (EHA) in Milan, Italy. Shares rose just over 60 percent to the new high. bluebird bio Inc (NASDAQ:BLUE) weekly performance is 41.23%. On last trading day company shares ended up $34.46. Analysts mean target price for the company is $43.25. bluebird bio Inc (NASDAQ:BLUE) distance from 50-day simple moving average (SMA50) is 57.59%.